Healthy stem cell donors start leukapheresis 4-5 days after starting G-CSF based on the peripheral blood CD34 þ cell count (PBCD34). Data from 137 harvests (68 donors) were analyzed to determine correlation between pre-apheresis leukocytes (11.0-94.8 Â 10 9 /l; median 38.8) and platelets (49-374 Â 10 9 /l; median 180), and PBCD34 (3-276/ll; median 40). PBCD34 correlated positively with leukocytes (r ¼ 0.48; Po0.0001) and platelets (r ¼ 0.40; Po0.0001). When pre-apheresis leukocytes were X25 and platelets were X100, PBCD34 and CD34 þ collection were 5-276/ll (median 57) and 0.5-27.6 Â 10 6 /kg (median 4.7), respectively; significantly higher than PBCD34 of 3-74/ll (median 17) and CD34 þ collection of 0.2-8.9 Â 10 6 /kg (median 2.2) when leukocytes were o25 and/or platelets were o100. With leukocytes X25 and platelets X100, PBCD34 was low (o20/ll) 8% of the time, compared to 57% of the time with leukocytes o25 and/or platelets o100 (Po0.0001). Our data suggest that it is not always necessary to measure PBCD34 to guide leukapheresis in healthy donors because pre-apheresis leukocytes and platelets X25 and X100, respectively, are associated with excellent mobilization. When blood counts do not meet these criteria, PBCD34 should be determined prior to initiation of apheresis. 
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Peripheral blood stem cells (PBSC) have numerous advantages over marrow for allogeneic transplantation. 1, 2 The administration of granulocyte colony-stimulating factor (G-CSF) or granulocyte-macrophage colony-stimulating factor (GM-CSF) at doses of 5-16 mg/kg daily results in adequate mobilization of progenitor cells into the blood. [1] [2] [3] [4] [5] [6] Depending upon the collection goal, the harvest is completed in 1-2 sessions.
In the setting of autologous collections from patients, the best predictor of an adequate harvest is the pre-apheresis absolute peripheral blood CD34 þ cell count (PBCD34). [7] [8] [9] In a study of autologous collections, PBCD34 X20/ml resulted in 94% of patients harvesting the goal of 2 Â 10 6 CD34 þ cells/kg body weight in a single-apheresis procedure. 7 Surrogate markers of harvest adequacy such as the total leukocyte count and platelet count may not be particularly useful in predicting adequate CD34 þ cell collections in patients because of prior or concurrent chemotherapy exposure. Since this is not the case with normal donors, we wanted to determine if the pre-apheresis leukocyte and platelet counts can help predict CD34 þ collections in healthy individuals donating stem cells for their siblings.
Patients and methods

Donors
A total of 68 healthy sibling donors (137 collections) were treated with G-CSF at a dose of approximately 10 mg/kg daily (rounded off to the nearest vial size; 600-1440 mg; median 780 mg) between July 2001 and July 2003. They were donating hematopoietic stem cells for their HLAidentical siblings who were to undergo allogeneic transplantation. Leukapheresis was started on day 4. All donors signed an informed consent for the procedure. Laboratory parameters including complete blood count, PBCD34, and chemistry panels were obtained from all donors prior to each apheresis procedure. The data from these donors were analyzed retrospectively after approval from the Institutional Review Board.
Leukapheresis
Cobe Spectra cell separators (Gambro BCT, Lakewood, CO, USA) running the semiautomated mononuclear cell collection protocol (Version 6.1) according to the manufacturer's recommendations were used for leukapheresis. Large volume leukapheresis was performed at a blood flow rate of 70-100 ml/min. The apheresis product was analyzed in the stem cell processing laboratory to determine the hematocrit, platelet count, mononuclear cell count, CD34 þ cell count, and the CD34 þ collection efficiency. Leukapheresis was repeated the next day if necessary to achieve the target goal of 4-10 Â 10 6 CD34 þ cells/kg recipient ideal body weight; depending upon the particular regimen or protocol on which the patient was being treated.
Statistical analysis
For the purposes of analysis, each individual apheresis procedure was considered a separate event. The first apheresis procedures for each donor were analyzed separately to account for apheresis-induced thrombocytopenia. The data were analyzed for correlation and univariate and multivariate regression using SPSS version 12.0 for Windows. The w 2 analysis and Student's t-test were used to compare the two groups based on factors determined significant through regression analysis.
Results
Forty -two of the donors (62%) were male. The median age was 49 years (range, 17-69 years). The number of apheresis procedures performed per donor was 1 (n ¼ 23), 2 (n ¼ 29), 3 (n ¼ 9), 4 (n ¼ 6), or 5 (n ¼ 1). The volume of blood processed was B10 liters (n ¼ 4), 15 liters (n ¼ 90), or 20 liters (n ¼ 43). The total number of CD34 þ cells collected was 14-1703 Â 10 6 (median 278); corresponding to 0.2-27.6 Â 10 6 /kg patient ideal body weight (median 4.1). Table 1 shows the correlation between leukocyte count, platelet count, PBCD34, and number of CD34 þ cells collected. As expected, there was a strong positive correlation between PBCD34 and the total number of CD34 þ cells collected when all procedures were considered together, as well as when the first day and the subsequent days were considered separately. Overall, both the platelet and the leukocyte counts correlated positively with PBCD34 and the number of CD34 þ cells collected.
However, there was a noticeable difference by the day of apheresis. Platelets correlated weakly with PBCD34 but not with the number of CD34 þ cells collected on the first day. However, platelets correlated well with both parameters on subsequent days. On the other hand, leukocytes correlated well with PBCD34 and the total CD34 þ cell quantity collected on the first day. The relationship between the leukocyte count and PBCD34 weakened on subsequent days, and there was no correlation between leukocytes and the total number of CD34 þ cells collected on subsequent days. Figures 1 and 2 illustrate the relationship between blood counts and PBCD34 by day of apheresis.
Hematologic parameters, results of mobilization assessment, and collection results have been summarized in Table 2 . Not unexpectedly, platelets dropped significantly after the first day as a result of apheresis-induced depletion although leukocytes remained unchanged. As a result, the proportion of patients with 'favorable' counts (leukocytes X25 and platelets X100) also dropped. PBCD34 dropped too, and as a result, the number of CD34 þ cells collected. Overall, there was a strong relationship between favorable counts and PBCD34; this remained so on the first day and beyond. More importantly, the relationship between Table 1 Correlation between leukocyte count, platelet count, PBCD34 and the number of CD34+ cells collected Table 1 ). Squares represent the first day's values and triangles represent subsequent days' values. There is a positive correlation on the first day as well as on subsequent days.
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'unfavorable' counts (leukocytes o25 and/or platelets o100) and poor PBCD34 strengthened beyond the first day.
If PBCD34 X20/ml is arbitrarily considered the threshold above which the stem cell collection is likely to be very good, the sensitivity and specificity of using the combination of leukocytes X25 and platelets X100 to predict PBCD34 X 20/ml were between 74 and 82%, respectively. The positive predictive value of this combination of surrogate markers for determination of PBCD34 X20/ml was 92%.
Discussion
Our data suggest that there is a significant correlation between hematologic parameters and adequacy of CD34 þ cell mobilization in response to G-CSF stimulation in normal individuals. Healthy donors with pre-apheresis leukocytes of X25 Â 10 9 /l and pre-apheresis platelets of X100 Â 10 9 /l ('favorable' counts) are highly likely to have PBCD34 X20/ml; indicative of a very high likelihood of a good stem cell collection. Conversely, healthy donors with pre-apheresis leukocytes of o25 Â 10 9 /l and/or preapheresis platelets of o100 Â 10 9 /l ('unfavorable' counts) have Table 2 Relationship between leukocyte counts, platelets counts, and PBCD34 Figure 2 Correlation between the pre-apheresis platelet counts and PBCD34 (see Table 1 ). Squares represent the first day's values and triangles represent subsequent days' values. There is poor correlation on the first day but good correlation on subsequent days.
a significantly lower likelihood of having PBCD34 X20/ml; particularly beyond the first apheresis day. Thus, when hematologic parameters are favorable, apheresis can be commenced immediately without necessarily awaiting PBCD34 results. On the other hand, when hematologic parameters are not favorable, it may be worthwhile awaiting the PBCD34 result before commencing apheresis. Awaiting PBCD34 is somewhat less important on the first day because even unfavorable counts are associated with adequate PBCD34 in over 60% of donors. It is more important on subsequent days when unfavorable counts are associated with adequate PBCD34 less than 40% of the time.
It should be noted that the variability in the volume of blood processed does not have any direct bearing on the point of this analysis. Similarly, while the number of CD34 þ cells harvested per kg recipient weight has been mentioned in Table 1 , it does not have any relationship to the main point of the study because, among other things, it depends upon the weight of the patient.
Pre-apheresis leukocytes and platelets have not been found to be predictive of CD34 þ mobilization and collection in the autologous setting except in one study 7 where weak correlation was detected between pre-apheresis leukocytes and the total CD34 þ cell collection, in another study where the platelet count was associated with good stem cell collection after chemotherapy mobilization, 10 and in a third study where pre-mobilization leukocyte and platelet counts correlated with stem cell collection. 11 The last study 11 was unusual in that it looked at mobilization in previously autografted patients. In a study of normal donors undergoing growth factor mobilization, Anderlini et al 12 found that donors older than 55 years had a nearly four-fold risk of poor mobilization. Pre-apheresis leukocyte counts did not affect stem cell yield on multivariate analysis. There was no mention of any relationship between pre-apheresis platelets and stem cell collection. Given that megakaryocytes produce the receptor for G-CSF, and that G-CSF has some role in megakaryopoiesis, it is possible that the role of the platelet count found here simply reflects the responsiveness of the marrow to exogenously administered G-CSF. 13, 14 In summary, our study demonstrates that for normal donors, a pre-apheresis leukocyte of at least 25 Â 10 9 /l and a platelet count of at least 100 Â 10 9 /l predicts a peripheral blood CD34 þ cell count of at least 20/ml in over 90% of donors.
